Abstract:BACKGROUND:Atherosclerosis is a chronic inflammatory disease, in which macrophages determine the progression of atherosclerotic plaques. However, no studies have investigated how METTL3 (methyltransferase like 3) in macrophages affects atherosclerotic plaque formation in vivo. Additionally, whether Braf mRNA is modified by METTL3-dependent N6-methyladenosine (m6A) methylation remains unknown.METHODS:We analyzed single-cell sequencing data of atherosclerotic plaques in mice fed with a high fat diet for different periods. Mettl3fl/fl Lyz2cre Apoe-/- mice and littermate control Mettl3fl/fl Apoe-/- mice were generated and fed high fat diet for 14 weeks. In vitro, we stimulated peritoneal macrophages with ox-LDL (oxidized low-density lipoprotein) and tested the mRNA and protein expression levels of inflammatory factors and molecules regulating ERK (extracellular signal-regulated kinase) phosphorylation. To find METTL3 targets in macrophages, we performed m6A-methylated RNA immunoprecipitation sequencing and m6A-methylated RNA immunoprecipitation-qPCR. Further, point mutation experiments were used to explore m6A-methylated adenine. Using RNA immunoprecipitation assay, we explored m6A methylation-writing protein bound to Braf mRNA.RESULTS:In vivo, METTL3 expression in macrophages increased with the progression of atherosclerosis. Myeloid cell-specific METTL3 deletion negatively regulated atherosclerosis progression and the inflammatory response. In vitro, METTL3 knockdown or knockout in macrophages attenuated ox-LDL-mediated ERK phosphorylation rather than JNK (c-Jun N-terminal kinase) and p38 phosphorylation and reduced the level of inflammatory factors by affecting BRAF protein expression. The negative regulation of inflammation response caused by METTL3 knockout was rescued by overexpression of BRAF. In mechanism, METTL3 targeted adenine (39725126 in chromosome 6) on the Braf mRNA. Then, YTHDF1 could bind to m6A-methylated Braf mRNA and promoted its translation.CONCLUSIONS:Myeloid cell-specific Mettl3 deficiency suppressed hyperlipidemia-induced atherosclerotic plaque formation and attenuated atherosclerotic inflammation. We identified Braf mRNA as a novel target of METTL3 in the activation of the ox-LDL-induced ERK pathway and inflammatory response in macrophages. METTL3 may represent a potential target for the treatment of atherosclerosis.

METTL3-mediated m6A modification enhances lncRNA H19 stability to promote endothelial cell inflammation and pyroptosis to aggravate atherosclerosis

Methyltransferase Like 3-Mediated N6-methylatidin Methylation Inhibits Vascular Smooth Muscle Cells Phenotype Switching Via Promoting Phosphatidylinositol 3-Kinase Mrna Decay.

Methyltransferase-like 14 silencing relieves the development of atherosclerosis via m6A modification of p65 mRNA

METTL14 aggravates endothelial inflammation and atherosclerosis by increasing FOXO1 N6-methyladeosine modifications

METTL14 Mediated M6a Modification to LncRNA ZFAS1/ RAB22A: A Novel Therapeutic Target for Atherosclerosis

METTL14 Suppresses Pyroptosis and Diabetic Cardiomyopathy by Down-Regulating TINCR Lncrna

RNA-m6A modification of HDGF mediated by Mettl3 aggravates the progression of atherosclerosis by regulating macrophages polarization via energy metabolism reprogramming

N6-Methyladenosine Methyltransferase METTL3 Promotes Angiogenesis and Atherosclerosis by Upregulating the JAK2/STAT3 Pathway via m6A Reader IGF2BP1

RNA N 6 -methyladenosine modulates endothelial atherogenic responses to disturbed flow in mice

METTL3-dependent N 6 -methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium

METTL3 (methyltransferase Like 3)-Dependent N6-Methyladenosine Modification on Braf Mrna Promotes Macrophage Inflammatory Response and Atherosclerosis in Mice.

METTL3 and ALKBH5 Oppositely Regulate M(6)a Modification of TFEB Mrna, Which Dictates the Fate of Hypoxia/reoxygenation-Treated Cardiomyocytes

Mettl14 Mediates the Inflammatory Response of Macrophages in Atherosclerosis Through the NF-κB/IL-6 Signaling Pathway

Mettl3-Mediated M6a Modification Plays a Role in Lipid Metabolism Disorders and Progressive Liver Damage in Mice by Regulating Lipid Metabolism-Related Gene Expression

Mechanisms of METTL14‐Mediated m6A Modification in Promoting Iron Overload‐Induced Lipid Peroxidative Damage in Vascular Endothelial Cells to Aggravate Atherosclerosis

The M6a Methyltransferase METTL3 Modifies PGC-1α Mrna Promoting Mitochondrial Dysfunction and Oxldl-Induced Inflammation in Monocytes

Mettl3/Mettl14 Transactivation and M 6 A-Dependent TGF-β1 Translation Aggravate Non-Alcoholic Steatohepatitis to Fibrosis Transition

The methyltransferase METTL3 regulates endothelial cell proliferation and inflammation via m6A RNA methylation-mediated TRAF1 expression

Mettl3/Mettl14 Transactivation and M 6A-Dependent TGF-β1 Translation Aggravate Non-Alcoholic Steatohepatitis to Fibrosis Transition

Role of METTL3-Dependent N6-Methyladenosine mRNA Modification in the Promotion of Angiogenesis

Methyltransferase-Like 3-Mediated N6-Methyladenosine RNA Methylation Regulates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Pyroptosis by Targeting PTEN